Tempus AI

In a manuscript published in Nature Portfolio Precision Oncology, collaborators from Yale School of Medicine leveraged RNA-seq data from our real-world database of diverse human malignancies and identified 40 tumors with rearrangements involving RASGRF1 or the related RASGRF2 predicted to generate chimeric proteins. Findings provide insights about the tissue distribution, structural diversity, and oncogenic mechanisms of RASGRF fusions. As cell models driven by these fusions are sensitive to MAPK pathway inhibition, oncogenic RASGRF fusions may represent a therapeutic target in rare molecular subsets of cancer. Read the publication here: https://tempus.co/4cbuf2A

Today is #WorldCancerDay. It's fitting that right now, more than 600 Tempus team members are gathered in Chicago for our Global Sales Meeting. We had the privilege of hosting Romy Leroy for a "Patient Perspective" session, hosted by Dr. Gary Grad. Romy was diagnosed with stage 4, triple-negative breast cancer and after receiving her test results from Tempus, was put on a immunotherapy/chemo combination treatment. She now has no evidence of disease. Romy’s story is a living reminder of our 'why.' On #WorldCancerDay and every day, the Tempus team is dedicated to helping make sure patients are on the right drug at the right time, so they can live longer and healthier lives.

Uncover critical insights now that can help accelerate innovation, and improve patient outcomes. Dive into a library of multimodal records that are available for immediate research use. Take action now in Lens: https://tempus.co/3LYHjxP

Meet Jijnes Patel, VP of Tempus OS. Jig leads our OS organization, driving the development of platform technologies that power Tempus’ products—including Data Governance, Compute, and Generative AI. His passion for innovative problem-solving and making a meaningful impact inspires his work every day, as he designs solutions that accelerate the future of precision medicine. Hear more from Jig about his #LifeAtTempus: 

Paige Predict is a suite of digital pathology AI applications designed for #NGS workflows. In a new article, Razik Yousfi, Caitlin McWilliams, and SIQI LIU take a deep dive into Paige Predict’s digital biomarker solution that predicts over 1,600 biomarkers across cancer types. This application analyzes a single, digitized hematoxylin-and-eosin (H&E) stained pathology image, enabling rapid biomarker screening at scale. Read now: https://tempus.co/4a7UyEl

Alain Silk will be joining Friends of Cancer Research as a panelist at next week’s “Modernizing Oncology Endpoints: Pathways for Evidence and Policy.” Attend the session, “AI-Enabled Tumor Assessments: Opportunities and Challenges for Incorporation into Clinical Trials,” to hear insights from Alain and fellow panelists on the Friends ai.RECIST Project and opportunities to integrate AI-enabled tumor assessment tools into clinical trials—supporting more efficient trial operations and the development of novel endpoints. Register here: https://bit.ly/4qU7kx5 #FriendsEndpoints26

We’re excited to share results from a study demonstrating that our algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI), and PD-L1. The new clinical validation results demonstrate that IPS consistently outperforms conventional biomarkers, highlighting its potential to change the way physicians can identify patients most likely to benefit from immunotherapy. Learn more: https://tempus.co/4rmFfyJ

A new case study in the Lens Library explores resistance mechanisms to antibody-drug conjugates (ADCs) in patients with urothelial cancer. Using real-world data in Tempus Lens, researchers analyzed more than 1,300 patient records to identify genomic and transcriptomic markers of ADC response. The analysis revealed key molecular distinctions between responders and non-responders, providing insights that can help life sciences companies: ◾Refine inclusion criteria for future clinical trials ◾Develop rational combination strategies ◾Inform the design of next-generation therapeutics Access the full study in the Lens Library here: https://tempus.co/4bQeDBt

We’re thrilled to be named a Built In Best Place to Work for 2026. Creating an environment where passionate and talented people can do their best work directly fuels our mission to help patients live healthier lives. Learn more about #LifeAtTempus: https://lnkd.in/eZPbsUe9

January is Cervical Cancer Awareness Month, a time to recognize the ongoing efforts to improve outcomes for patients with this difficult disease. In a study published in the International Journal of Gynecological Cancer, researchers utilized the Tempus Lens multimodal database to explore the molecular landscape of patients with advanced cervical cancer treated with immunotherapy. By characterizing the somatic and immune landscape in a diverse cohort, the research suggests the biological differences across metastatic sites could lead to differential responses to immunotherapy regimens. Access the manuscript here: https://tempus.co/4jXazBy